nitrosamines – Page 5

Nitrosamine risk assessment incomplete during regulatory inspection – FDA/EMA nitrosamine expectations

Navigating FDA and EMA Expectations for Nitrosamine Risk Assessments During Inspections The pharmaceutical industry faces increasing scrutiny regarding the presence of nitrosamines in drug products, particularly during regulatory inspections. Inadequate…

Nitrosamine risk assessment incomplete during ongoing surveillance – preventing product recall

Navigating Incomplete Nitrosamine Risk Assessments during Ongoing Surveillance to Prevent Product Recalls Nitrosamines have emerged as a critical concern in pharmaceutical manufacturing, especially given their potential to form during the…

Nitrosamine risk assessment incomplete during risk assessment – risk mitigation and control strategy

Strategies for Addressing Incomplete Nitrosamine Risk Assessments in Pharmaceutical Manufacturing Nitrosamines pose a significant risk in pharmaceutical manufacturing, particularly concerning the use of certain raw materials. When nitrosamine risk assessment…

Regulatory query on nitrosamines during risk assessment – risk mitigation and control strategy

Effective Strategies for Managing Nitrosamine Risks during Regulatory Assessments Pharmaceutical manufacturers are increasingly faced with regulatory inquiries surrounding the presence of nitrosamines in raw materials. These compounds pose significant risks…

Regulatory query on nitrosamines during supplier audit – risk mitigation and control strategy

Effective Management Strategies for Nitrosamine Risks During Supplier Audits Nitrosamines have emerged as a critical concern in pharmaceutical manufacturing, particularly during supplier audits. The potential for contamination poses severe regulatory…

Regulatory query on nitrosamines during submission support – CAPA for nitrosamine findings

Practical Playbook for Managing Nitrosamine Regulatory Queries in Pharmaceutical Submissions Nitrosamines have emerged as a critical concern in pharmaceutical manufacturing due to their potential carcinogenic effects. The increased scrutiny from…

Analytical method sensitivity questioned during regulatory inspection – preventing product recall

Addressing Analytical Method Sensitivity Concerns Identified During Regulatory Inspections In recent regulatory inspections, questions surrounding the sensitivity of analytical methods have led to increased scrutiny of manufacturing processes, particularly in…

Segregation controls inadequate during investigation – CAPA and system strengthening

Strengthening Segregation Controls During Investigations: A Playbook for Pharma Professionals In the pharmaceutical manufacturing landscape, inadequate segregation controls during investigations can lead to significant compliance issues and potential product contamination.…

Traceability records incomplete during investigation – CAPA and system strengthening

Addressing Incomplete Traceability Records during Investigations: A Comprehensive Guide In the pharmaceutical manufacturing landscape, maintaining rigorous traceability records is critical for ensuring quality and regulatory compliance. The challenge of incomplete…

Material mix-up incident reported during investigation – CAPA and system strengthening

Actionable Playbook for Managing Material Mix-Up Incidents in Pharma Material mix-up incidents present significant challenges in pharmaceutical manufacturing, leading to potential risks in product quality and patient safety. The need…

Segregation controls inadequate during warehouse operations – preventing repeat mix-up events

Effective Strategies for Addressing Inadequate Segregation Controls During Warehouse Operations In pharmaceutical manufacturing, proper segregation controls are critical to ensuring material traceability and preventing mix-up events. However, inadequate segregation controls…

Reconciliation discrepancies during dispensing – inspection defense documentation

Addressing Reconciliation Discrepancies during Dispensing: A Comprehensive Playbook In pharmaceutical manufacturing, reconciliation discrepancies during dispensing can lead to significant production delays, quality issues, and regulatory scrutiny. Timely identification and resolution…